Advanced Cell Technology (ACT) is a biotechnology company that specializes in developing cellular therapies to treat human diseases and was one of the first companies to run an FDA-approved clinical trial based on embryonic stem cells. The corporate offices and principal laboratory for ACT are located in Marlborough, Massachusetts, where the company is headed by Ted Myles (interim [Page 26]president, chief financial officer, and executive vice president of Corporate Development) who began at ACT in June 2013, and Robert Lanza, MD (chief scientific officer), who began working at ACT in 1999. Lanza is also an adjunct professor at the Wake Forest University School of Medicine in the Institute of Regenerative Medicine. ACT owns or licenses over 150 patents, including a broad patent for producing retinal ...